Lv15
40 积分 2026-05-03 加入
Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma
1天前
已完结
Molecular mechanisms and pathogenesis of MASH
3天前
已完结
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
3天前
已完结
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
3天前
已完结
An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC
3天前
已完结
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
5天前
已完结
Cost-Utility Analysis of Noninvasive Tests to Initiate Hepatocellular Carcinoma Surveillance in Metabolic Dysfunction-Associated Steatotic Liver Disease
5天前
已完结
Patient-derived organoids for hepatobiliary cancers: Molecular mechanisms, translational applications and precision therapeutics
6天前
已完结
The importance of preclinical models for cholangiocarcinoma drug discovery
7天前
已完结
Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study
7天前
已完结